Literature DB >> 25606283

A postmenopausal osteoporotic woman losing bone mineral density despite bisphosphonates.

Psm Lai1, T Nagammai1, Sr Vethakkan1.   

Abstract

Bisphosphonates are pyrophosphate analogues, with a strong affinity for bones. They inhibit bone resorption and are currently the first choice of treatment for osteoporosis. Bisphosphonates should be taken in a specific manner and for at least one year to be effective in the maintenance and improvement of bone mineral density (BMD), as well as for protection against fractures. We report a case of a postmenospausal osteoporotic woman who lost BMD despite being on bisphosphonate therapy for eight years, highlighting issues that a primary care doctor needs to address before deciding on the next best option.

Entities:  

Keywords:  bisphosphonate; bone mineral density; osteoporosis; postmenopausal

Year:  2013        PMID: 25606283      PMCID: PMC4170476     

Source DB:  PubMed          Journal:  Malays Fam Physician        ISSN: 1985-2274


  12 in total

1.  The impact of pharmacist intervention on the use of activated vitamin D in a tertiary referral hospital in Malaysia.

Authors:  Jing Yong Siow; Pauline Siew Mei Lai; Siew Slang Chua; Siew Pheng Chan
Journal:  Int J Pharm Pract       Date:  2009-10

2.  Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.

Authors:  P S M Lai; S S Chua; S P Chan
Journal:  J Clin Pharm Ther       Date:  2012-03-01       Impact factor: 2.512

3.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Authors:  J Y Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; J P Devogelaer; M Diaz Curiel; A Sawicki; S Goemaere; O H Sorensen; D Felsenberg; P J Meunier
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

4.  Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.

Authors:  Michael F Holick; Ethel S Siris; Neil Binkley; Mary K Beard; Aliya Khan; Jennifer T Katzer; Richard A Petruschke; Erluo Chen; Anne E de Papp
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

Review 5.  Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

Authors:  Anthony B Hodsman; Douglas C Bauer; David W Dempster; Larry Dian; David A Hanley; Steven T Harris; David L Kendler; Michael R McClung; Paul D Miller; Wojciech P Olszynski; Eric Orwoll; Chui Kin Yuen
Journal:  Endocr Rev       Date:  2005-03-15       Impact factor: 19.871

6.  Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

Authors:  P S M Lai; S S Chua; Y Y Chew; S P Chan
Journal:  J Clin Pharm Ther       Date:  2010-10-26       Impact factor: 2.512

7.  Compliance with drug therapy for postmenopausal osteoporosis.

Authors:  D Weycker; D Macarios; J Edelsberg; G Oster
Journal:  Osteoporos Int       Date:  2006-07-22       Impact factor: 4.507

Review 8.  Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

Authors:  Mark P Ettinger
Journal:  Arch Intern Med       Date:  2003-10-13

Review 9.  Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.

Authors:  Anthony I Sebba
Journal:  Clin Ther       Date:  2008-03       Impact factor: 3.393

10.  Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates.

Authors:  George A Heckman; Alexandra Papaioannou; Rolf J Sebaldt; George Ioannidis; Annie Petrie; Charlie Goldsmith; Jonathan D Adachi
Journal:  BMC Musculoskelet Disord       Date:  2002-02-08       Impact factor: 2.362

View more
  1 in total

1.  Detection and residence time of bisphosphonates in bone of horses.

Authors:  Heather K Knych; Jennifer Janes; Laura Kennedy; Daniel S McKemie; Rick M Arthur; Monika A Samol; Francisco A Uzal; Mary Scollay
Journal:  J Vet Diagn Invest       Date:  2022-01       Impact factor: 1.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.